Abstract
Quantitative structure–activity relationship (QSAR) analysis has been carried out on a series of conformationally restricted 1,5-diaryl pyrazoles reported as selective cyclooxygenase-2 (COX-2) inhibitors in order to explore the selectivity requirements for COX-2 inhibition among these congeners. QSAR analysis was based on regression analysis between various computed physicochemical and topological descriptors and biological activity. Derived QSAR models evinced a satisfactory correlation of COX-2 inhibitory potency with a three-dimensional (3D) spatial descriptor, std_dim3, and a two-dimensional (2D) partial charge descriptor, PEOE_VSA-1. Balaban J, a highly discriminating topological descriptor, was found to play an imperative role in governing both COX-1 inhibitory potency as well as selective inhibition of COX-2 over COX-1. The selective COX-2 inhibition could be influenced by the size, shape, and polarizability of the whole molecules and was discerned by the contribution of molar refractivity (MR), Balaban J descriptors. The findings are in good consonance with earlier X-ray crystallographic investigations of binding mode of these types of selective COX-2 inhibitors. Results discussed herein bring important structural insights to aid the design and development of novel COX-2 inhibitors.
Similar content being viewed by others
References
Bertenshaw SR, Talley JJ, Rogier DJ, Graneto MJ, Koboldt CM, Zhang Y et al (1996) Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors. Bioorg Med Chem Lett 6:2827–2830. doi:10.1016/S0960-894X(96)00530-6
Botting JH (1999) Nonsteroidal antiinflammatory agents. Drugs Today (Barc) 35:225–235
Dannhardt G, Kiefer W (2000) Cyclooxygenase inhibitors—current status and future prospectus. Eur J Med Chem 36:109–126. doi:10.1016/S0223-5234(01)01197-7
Garg R, Kurup A, Mekapati SB, Hansch C (2003) Cycloxygenase (COX) inhibitors: a comparative QSAR study. Chem Rev 103:703–731. doi:10.1021/cr020464a
Kurumbail RG, Pak JY, Gildehaus D, Miyashiro JM, Stevens AM, Gierse JK et al (1996) Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 384:644–648. doi:10.1038/384644a0
Manivannan E, Prasanna S, Chaturvedi SC (2004) Rationalization of physico-chemical properties of 5,6-diarylthiazolo [3,2-b]-1, 2,4-triazoles towards cyclooxygenase-2 (COX-2) inhibition. Indian J Biochem Biophys 41:179–183
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Doctor S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rojers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5 diaryl pyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methyl phenyl)-3-(triflouro methyl)-1H-pyrazol-1-yl] benzene sulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347–1365. doi:10.1021/jm960803q
Prasanna S, Manivannan E, Chaturvedi SC (2004a) Quantitative structure-activity relationship analysis of a series of 2,3-diaryl benzopyran analogues as novel selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 14:4005–4011. doi:10.1016/j.bmcl.2004.05.059
Prasanna S, Manivannan E, Chaturvedi SC (2004b) QSAR analysis of 2,3-diaryl benzopyrans/pyrans as selective COX-2 inhibitors based on semiempirical AM1 Calculations. QSAR Comb Sci 23:621–628. doi:10.1002/qsar.200430887
Prasanna S, Manivannan E, Chaturvedi SC (2004c) QSAR analysis of some fused pyrazoles as cyclooxygenase inhibtors: a Hansch approach. Arch Pharm Pharm Med Chem 337:440–444. doi:10.1002/ardp.200400887
Prasanna S, Manivannan E, Chaturvedi SC (2005a) QSAR studies on structurally similar 2-(4-methanesulfonylphenyl) pyran-4-ones as selective COX-2 inhibitors: a Hansch approach. Bioorg Med Chem Lett 15:313–320. doi:10.1016/j.bmcl.2004.10.077
Prasanna S, Manivannan E, Chaturvedi SC (2005b) Quantitative structure-activity relationship analysis of 2,3 diaryl indoles as selective cyclooxygenase-2 inhibitors. J Enzyme Inhib Med Chem 20:455–461. doi:10.1080/14756360500277251
Prasanna S, Manivannan E, Chaturvedi SC (2005c) Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: a comprehensive analysis. Drug Dev Res 64:220–231. doi:10.1002/ddr.10432
Prasanna S, Manivannan E, Chaturvedi SC (2005d) QSAR analyses of conformationally restricted 1,5-diarylpyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands. Bioorg Med Chem Lett 15:2097–2102. doi:10.1016/j.bmcl.2005.02.035
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W et al (1999) The discovery of rofecoxib, [MK 996, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 9:1773–1778. doi:10.1016/S0960-894X(99)00288-7
Talley JJ, Brown DL, Carter JS, Granteo MJ, Koboldt CM, Masferrer JL et al (2000a) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43:775–777. doi:10.1021/jm990577v
Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS et al (2000b) N-[[(5-Methyl-3-phenyl] sulfonyl] propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parentral administration. J Med Chem 43:1661–1663
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of Asprin-like drugs. Nature 231:232–235
Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120. doi:10.1146/annurev.pharmtox.38.1.97
Acknowledgements
One of the authors (E. Manivannan) would like to thank the University Grants Commission (UGC), New Delhi for the financial support for this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manivannan, E., Chaturvedi, S.C. QSAR analysis of centrally fused 1,5-diaryl pyrazoles for cyclooxygenase inhibition using MOE-Qua-SAR descriptors. Med Chem Res 18, 396–405 (2009). https://doi.org/10.1007/s00044-008-9136-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-008-9136-x